Journal of Medical Economics, Volume 23, Issue 11 (2020)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Journal of Medical Economics, Volume 23, Issue 11 (2020)

See all volumes and issues
Vol 27, 2024 Vol 26, 2023 Vol 25, 2022 Vol 24, 2021 Volume 23, 2020 Vol 22, 2019 Vol 21, 2018 Vol 20, 2017 Vol 19, 2016 Vol 18, 2015 Vol 17, 2014 Vol 16, 2013 Vol 15, 2012 Vol 14, 2011 Vol 13, 2010 Vol 12, 2009 Vol 11, 2008 Vol 10, 2007 Vol 9, 2006 Vol 8, 2005 Vol 7, 2004 Vol 6, 2003 Vol 5, 2002 Vol 4, 2001 Vol 3, 2000 Vol 2, 1999 Vol 1, 1998
Download citations Download PDFs Download issue

Special Section: Pricing Methods in Outcome-Based Contracting: The Six Delta Platform : Methods and Modeling

Editorial
The six Delta platform for outcome-based contracting for pharmaceuticals
Nimer S. Alkhatib & Ivo Abraham
Pages: 1209-1214
Published online: 29 Sep 2020
First Page PreviewforThe six Delta platform for outcome-based contracting for pharmaceuticals | Full Text | References | PDF (790.4 KB) | EPUB
  • 4617 Views
  • 10 CrossRef citations
  • 0Altmetric
Free Access
Article
Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing
Nimer S. Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride, Sandipan Bhattacharjee & Ivo Abraham
Pages: 1215-1222
Published online: 08 Sep 2020
AbstractforPricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing | Full Text | References | PDF (1.3 MB) | EPUB | Supplemental
  • 2179 Views
  • 8 CrossRef citations
  • 0Altmetric
Free Access
Article
Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing
Nimer S. Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride, Sandipan Bhattacharjee & Ivo Abraham
Pages: 1223-1229
Published online: 08 Sep 2020
AbstractforPricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing | Full Text | References | PDF (1.2 MB) | EPUB | Supplemental
  • 1273 Views
  • 6 CrossRef citations
  • 0Altmetric
Free Access
Article
Pricing methods in outcome-based contracting: δ3: reference-based pricing
Nimer S. Alkhatib, Brian Erstad, Kenneth Ramos, Ali McBride, Sandipan Bhattacharjee, Marion Slack & Ivo Abraham
Pages: 1230-1236
Published online: 08 Sep 2020
AbstractforPricing methods in outcome-based contracting: δ3: reference-based pricing | Full Text | References | PDF (983.2 KB) | EPUB | Supplemental
  • 1493 Views
  • 8 CrossRef citations
  • 0Altmetric
Free Access
Article
Pricing methods in outcome-based contracting: δ4: safety-based pricing
Nimer S. Alkhatib, Sandipan Bhattacharjee, Ali McBride, Kenneth Ramos, Marion Slack, Brian Erstad & Ivo Abraham
Pages: 1237-1245
Published online: 08 Sep 2020
AbstractforPricing methods in outcome-based contracting: δ4: safety-based pricing | Full Text | References | PDF (1.1 MB) | EPUB | Supplemental
  • 1089 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access
Article
Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing
Nimer S. Alkhatib, Ali McBride, Sandipan Bhattacharjee, Kenneth Ramos, Brian Erstad, Marion Slack, Dean Billheimer & Ivo Abraham
Pages: 1246-1255
Published online: 08 Sep 2020
AbstractforPricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing | Full Text | References | PDF (1.9 MB) | EPUB | Supplemental
  • 950 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access
Article
Pricing methods in outcome-based contracting: δ6: adherence-based pricing
Nimer S. Alkhatib, Marion Slack, Sandipan Bhattacharjee, Brian Erstad, Kenneth Ramos, Ali McBride & Ivo Abraham
Pages: 1256-1265
Published online: 10 Sep 2020
AbstractforPricing methods in outcome-based contracting: δ6: adherence-based pricing | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
  • 1145 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access
Article
Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)
Nimer S. Alkhatib, Ali McBride, Marion Slack, Sandipan Bhattacharjee, Brian Erstad, Kenneth Ramos & Ivo Abraham
Pages: 1266-1272
Published online: 08 Sep 2020
AbstractforPricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs) | Full Text | References | PDF (1 MB) | EPUB
  • 1129 Views
  • 2 CrossRef citations
  • 0Altmetric
Free Access

Methods and Modelling

Article
Dehydrated human amnion and chorion allograft versus standard of care alone in treatment of Wagner 1 diabetic foot ulcers: a trial-based health economics study
Marissa J. Carter
Pages: 1273-1283
Published online: 08 Aug 2020
AbstractforDehydrated human amnion and chorion allograft versus standard of care alone in treatment of Wagner 1 diabetic foot ulcers: a trial-based health economics study | Full Text | References | PDF (1.4 MB) | EPUB
  • 2132 Views
  • 4 CrossRef citations
  • 0Altmetric
Open Access

Health Technology

Article
Cost-utility analysis of normothermic liver perfusion with the OrganOx metra compared to static cold storage in the United Kingdom
Mehdi Javanbakht, Atefeh Mashayekhi, Miranda Trevor, Michael Branagan-Harris & Jowan Atkinson
Pages: 1284-1292
Published online: 27 Aug 2020
AbstractforCost-utility analysis of normothermic liver perfusion with the OrganOx metra compared to static cold storage in the United Kingdom | Full Text | References | PDF (1.6 MB) | EPUB
  • 2837 Views
  • 22 CrossRef citations
  • 0Altmetric
Free Access

Healthcare Systems

Article
Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma
Masakazu Yamada, Tadashi Nakano, Hiroyuki Matsuda, Seok-Won Kim & Yasutaka Takagi
Pages: 1293-1301
Published online: 27 Aug 2020
AbstractforCost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma | Full Text | References | PDF (1.3 MB) | EPUB
  • 2632 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access

Gastroenterology

Article
Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand
Pochamana Phisalprapa, Chayanis Kositamongkol, Julajak Limsrivilai, Satimai Aniwan, Phunchai Charatcharoenwitthaya, Pises Pisespongsa, Taya Kitiyakara, Suporn Treepongkaruna & Nathorn Chaiyakunapruk
Pages: 1302-1310
Published online: 13 Aug 2020
AbstractforCost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand | Full Text | References | PDF (1.9 MB) | EPUB | Supplemental
  • 2471 Views
  • 3 CrossRef citations
  • 0Altmetric
Free Access

Diabetes

Article
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective
Johan Jendle, Åsa Ericsson, Bertil Ekman, Stefan Sjöberg, Jens Gundgaard, João da Rocha Fernandes, Ann-Charlotte Mårdby, Barnaby Hunt, Samuel J. P. Malkin & Maria Thunander
Pages: 1311-1320
Published online: 14 Sep 2020
AbstractforReal-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective | Full Text | References | PDF (1.7 MB) | EPUB | Supplemental
  • 2758 Views
  • 7 CrossRef citations
  • 0Altmetric
Open Access

Oncology

Article
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective
Boon Piang Cher, Kar Yee Gan, Mohamed Ismail Abdul Aziz, Liang Lin, William Ying Khee Hwang, Li Mei Poon & Kwong Ng
Pages: 1321-1329
Published online: 25 Aug 2020
AbstractforCost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective | Full Text | References | PDF (1.8 MB) | EPUB | Supplemental
  • 4019 Views
  • 16 CrossRef citations
  • 0Altmetric
Free Access
Article
Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore
Mohamed Ismail Abdul Aziz, Wayne Yong Xiang Foo, Chee Keong Toh, Wan-Teck Lim & Kwong Ng
Pages: 1330-1339
Published online: 21 Sep 2020
AbstractforCost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore | Full Text | References | PDF (1.4 MB) | EPUB
  • 2987 Views
  • 6 CrossRef citations
  • 0Altmetric
Free Access
Article
Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system
Rodrigo Shimabukuro Ho, Mariana Mioti Sebastião, João Paulo Venezian de Carvalho, Tomás Neves & Micha Nussbaum
Pages: 1340-1344
Published online: 26 Sep 2020
AbstractforCost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system | Full Text | References | PDF (764 KB) | EPUB | Supplemental
  • 2981 Views
  • 3 CrossRef citations
  • 0Altmetric
Open Access

Health Financing

Article
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance – the perspective of private and public payers
Nirmish R. Shah, Menaka Bhor, Dominick Latremouille-Viau, Vikash Kumar Sharma, Gary A. Puckrein, Patrick Gagnon-Sanschagrin, Ankur Khare, Mukesh Kumar Singh, Elizabeth Serra, Mikhaïl Davidson, Liou Xu & Annie Guerin
Pages: 1345-1355
Published online: 09 Sep 2020
AbstractforVaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance – the perspective of private and public payers | Full Text | References | PDF (1.7 MB) | EPUB | Supplemental
  • 3318 Views
  • 10 CrossRef citations
  • 0Altmetric
Free Access

Neurology

Article
Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database
Shonda A. Foster, Chi-Chang Chen, Yao Ding, Oksana Mason, Catherine B. McGuiness, Paula Morrow, Wenyu Ye, Rolin L. Wade, Timothy R. Smith & Shivang Joshi
Pages: 1356-1364
Published online: 12 Sep 2020
AbstractforEconomic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database | Full Text | References | PDF (1.3 MB) | EPUB
  • 2429 Views
  • 7 CrossRef citations
  • 0Altmetric
Open Access

Cardiovascular

Article
Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US
Dejan Milentijevic, Guillaume Germain, François Laliberté, Brahim K. Bookhart, Sean D. MacKnight, Jenkin Tsang & Patrick Lefebvre
Pages: 1365-1374
Published online: 29 Sep 2020
AbstractforHealthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US | Full Text | References | PDF (926.1 KB) | EPUB | Supplemental
  • 1711 Views
  • 3 CrossRef citations
  • 0Altmetric
Open Access

Explore articles